Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities

References

• Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 387–400
   PubMed Web of Science ®Google Scholar
• Alexopoulos, GS, Privitera, W, Ventura, D, Bose, A, Wang, Q. 2003. Double-blind comparison of escitalopram 10 mg/day and optimally-dosed sertraline 50–200 mg/day in the treatment of major depressive disorder. Poster presented at the 42nd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico.
   Google Scholar
• American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th ed rev. Washington, DC: American Psychiatric Association.
   Google Scholar
• Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression–A retrospective study. J Affect Disord 2005; 89: 183–188
   PubMed Web of Science ®Google Scholar
• Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003; 64 : 208–214
   PubMed Web of Science ®Google Scholar
• Anand A, Malison RT, McDougle CJ, Price LH. Antiglucocorticoid treatment of refractory depression with ketoconazole: a case report. Biol. Psychiatry 1995; 37: 338–340
   Google Scholar
• Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19–36
   PubMed Web of Science ®Google Scholar
• Anderson I. Meta-analytical studies on new antidepressants. Br Med Bull 2001; 57: 161–178
   PubMed Web of Science ®Google Scholar
• Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychpharmacol 1994; 8: 238–249
   PubMed Web of Science ®Google Scholar
• Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibition compared with tricyclic antidepressants: a meta-analysis. Br Med J 1995; 310: 1433–1438
   PubMed Web of Science ®Google Scholar
• Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol 2002; 22: 393–399
   PubMedGoogle Scholar
• Anttila SAK, Leinonen EVJ. A review of the pharmacological and clinical profile of mirtazapine. CNS Drugs Rev 2001; 3: 249–264
   Google Scholar
• Arnold, LM, Lu, Y, Crofford, LJ, Wohlreich, M, Detke, MJ, Iyengar, S, Goldstein, DJ, for the Duloxetine Fibromyalgia Trial Group. 2004. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without depressive disorder. Arth Rheum, 50:2974–2984.
   PubMed Web of Science ®Google Scholar
• Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 2005; 3: 449–456
   PubMed Web of Science ®Google Scholar
• Asher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Sulser F. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395–401
   PubMedGoogle Scholar
• Auquier P, Robitail S, Llorca PM, Rive B. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Pract 2003; 7: 259–268
   PubMed Web of Science ®Google Scholar
• Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004; 13(Suppl 1)I102–116
   PubMedGoogle Scholar
• Bauer M, Whybrow PC, Angst J, Versiani M, Möller H-J, Task Force on Tretment Guidelines for Unipolar Depressive Disorders WFSBP. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of unipolar depressive disorder. Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002b; 3: 4–43
   Google Scholar
• Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 2002a; 3: 69–86
   PubMedGoogle Scholar
• Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of depression. Int J Neuropsychopharmacol 2001; 4: 337–345
   PubMed Web of Science ®Google Scholar
• Behnke K, Jensen GS, Graubaum HJ, Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther 2002; 19: 43–52
   PubMed Web of Science ®Google Scholar
• Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001; 21: 516–521
   PubMed Web of Science ®Google Scholar
• Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002; 52: 386–392
   PubMed Web of Science ®Google Scholar
• Benedictis E. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol 2000; 14: 61–66
   PubMed Web of Science ®Google Scholar
• Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000; 61: 656–663
   PubMed Web of Science ®Google Scholar
• Berzewski H, van MM, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997; 7(Suppl 1)S37–47
   PubMedGoogle Scholar
• Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17 : 65–69
   PubMedGoogle Scholar
• Bielski RJ, Ventura D, Chang DD. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004; 65: 1190–1196
   PubMed Web of Science ®Google Scholar
• Bitran D, Hilvers RJ, Kellogg CK. Anxiolytic effects of 3α-hydroxy-5α[β]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res 1991; 561: 157–161
   PubMed Web of Science ®Google Scholar
• Bjerkenstedt L, Edman GV, Alken RG, Mannel M. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci 2005; 255: 40–47
   PubMed Web of Science ®Google Scholar
• Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002; 159: 1869–1875
   PubMed Web of Science ®Google Scholar
• Bogaards JJ, Hissink EM, Briggs M, Weaver R, Jochemsen R, Jackson P, Bertrand M, van Bladeren PJ. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur J Pharm Sci 2000; 12: 117–124
   PubMed Web of Science ®Google Scholar
• Bogetto F, Bellino S, Revello RB, Patria L. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs 2002; 16: 273–283
   PubMedGoogle Scholar
• Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023–1029
   PubMed Web of Science ®Google Scholar
• Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JJG, Schatzberg AF. Dulxoetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005; 39: 43–53
   PubMed Web of Science ®Google Scholar
• Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther 2000; 22: 411–419
   PubMed Web of Science ®Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331–336
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrich-Luecke SK, Wong DT. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacolgy 2001; 25: 871–880
   PubMed Web of Science ®Google Scholar
• Chen, F, Larsen, MB, Neubauer, HA, Sinning, S, Plenge, P, Sánchez, C, Wiborg, O. 2004. Characterization of two overlapping S-citalopram binding sites on the serotonin transporter. 24th Congress of the CINP, Paris.
   Google Scholar
• Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, Malvini L, Barbui C. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2005; 19(4)D004185
   Google Scholar
• Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005; 21: 1659–1668
   PubMed Web of Science ®Google Scholar
• Croft H, Settle E, Jr, Houser I, Batey SR, Donahue RMJ, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained release bupropion and sertraline. Clin Ther 1999; 21: 643–658
   PubMed Web of Science ®Google Scholar
• Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 1997; 9: 157–164
   PubMedGoogle Scholar
• Czekalla J, Gastpar M, Hubner WD, Jager D. The effect of hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry 1997; 30(Suppl 2)86–88
   PubMedGoogle Scholar
• Deltito J, Beyer D. The scientific, quasi-scientific and popular literature on the use of St. John's Wort in the treatment of depression. J Affect Disord 1998; 51: 345–351
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002a; 63: 308–315
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002b; 36: 383–390
   PubMed Web of Science ®Google Scholar
• Dostert P, Benedetti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997; 7(Suppl 1)S23–35
   PubMed Web of Science ®Google Scholar
• Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. A prospective safety surveillance study of bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998; 59: 366–373
   PubMed Web of Science ®Google Scholar
• Edwards G, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57: 507–533
   PubMed Web of Science ®Google Scholar
• Einarson T. Comparison of extended relase venlafaxine, SSRIs and TCAs in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 1999; 21: 296–308
   PubMed Web of Science ®Google Scholar
• Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004; 19: 305–310
   PubMed Web of Science ®Google Scholar
• Eker SS, Akkaya C, Akgoz S, Sarandol A, Kirli S. Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder]. Turk Psikiyatri Derg 2005; 16: 153–163
   PubMed Web of Science ®Google Scholar
• Entsuah, R. 2004. Venlafaxine vs. SSRIs: Comparison of somatic symptom reduction [Abstract]. Congress of the American Psychiatric Association (APA), New York, USA.
   Google Scholar
• Entsuah A, Rudolph R, Hackett D, Miska S. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 1996; 11: 137–145
   PubMed Web of Science ®Google Scholar
• Entsuah R, Derivan A, Kikta D. Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients. Clin Ther 1998; 20: 517–526
   PubMedGoogle Scholar
• Entsuah, R, Huang, H, Willard, L. 2002. Venlafaxine and SSRIs: pooled remission analysis (meta-analysis of 31 studies of >7000 patients) [Abstract]. World Congress of Psychiatry (WCP), 24–29, August, Yokohama, Japan.
   Google Scholar
• Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997; 154: 1760–1762
   PubMed Web of Science ®Google Scholar
• Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J. Clin. Psychopharmacol. 2005a; 25: 441–447
   Google Scholar
• Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnson JA. 15 years clinical experience with bupropion HCl: From bupropion to bupropion SR to bupropion XL. Prime Care Companion J Clin Psychiatry 2005b; 7: 106–113
   PubMedGoogle Scholar
• Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998; 51: 267–285
   PubMed Web of Science ®Google Scholar
• Feiger AD, Heiser JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JM, Gibertini M. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J. Clin. Psychiatry 2003; 64: 243–249
   Google Scholar
• Feiger AD. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacol Bull 1996; 32: 659–665
   PubMed Web of Science ®Google Scholar
• Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry (suppl A) 1994; 55: 62–68
   PubMed Web of Science ®Google Scholar
• Feighner JP, Herbstein J, Damlouji N. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry 1985; 46: 206–209
   PubMed Web of Science ®Google Scholar
• Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 2000; 39: 413–427
   PubMed Web of Science ®Google Scholar
• Foulkes NS, Borjigin J, Snyder SH, Sassone-Corsi P. Rhythmic transcription: the molecular basis of circadian melatonin synthesis. Trends Neurosci 1997; 20: 487–492
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Carey TS, Lohr KN, Gaynes BN, Randolph LC. Discontinuation rates of selective serotonin reuptake inhibitors and other second generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. Int Clin Psychopharmacol 2005; 20: 59–69
   PubMed Web of Science ®Google Scholar
• Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once–daily dosage in comparison with sertraline. Pharmacopsychiatry 2005; 38: 78–86
   PubMed Web of Science ®Google Scholar
• Ghadirian AM, Engelsmann F, Dhar V, Filipini D, Keller R, Chouinard G, Murphy BEP. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry 1995; 37: 369–375
   PubMed Web of Science ®Google Scholar
• Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 2002; 7(Suppl 1)40–44
   PubMed Web of Science ®Google Scholar
• Guelfi JD, White C, Hackett D, Guichoux JY, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995; 56: 450–458
   PubMed Web of Science ®Google Scholar
• Guelfi JD, Ansseau M, Timmerman L, Korsgaard S. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Pharmacol 2001; 21: 425–431
   Google Scholar
• Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol 1998; 12 : 305–313
   PubMed Web of Science ®Google Scholar
• Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 2004; 10: 23–44
   PubMedGoogle Scholar
• Hamilton M. The Hamilton rating scale for depression. Assessment of depression, N Sartorius, TA Ban. Springer, Berlin 1986; 143–152
   Google Scholar
• Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143: 415–426
   PubMed Web of Science ®Google Scholar
• Heuser I, Deuschle M, Luppa P, Schweiger U, Standhardt H, Weber B. Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J Clin Endocrinol Metab 1998; 83: 3130–3133
   PubMed Web of Science ®Google Scholar
• Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910–916
   PubMed Web of Science ®Google Scholar
• Howell SR, Husbands GE, Scatina JA, Sisenwine SF. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993; 23: 349–359
   PubMed Web of Science ®Google Scholar
• Hyttel J, Bøgesø KP, Perregaard J, Sánchez C. The pharmacological effect of citalopram resides in the s-(+)-enantiomer. J Neural Transm [Gen Sect] 1992; 88: 157–160
   PubMed Web of Science ®Google Scholar
• Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry 2004; 61: 1235–1244
   PubMed Web of Science ®Google Scholar
• Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 338–345
   PubMed Web of Science ®Google Scholar
• Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. Pharmacopsychiatry 2001; 34: 96–103
   PubMed Web of Science ®Google Scholar
• Kasper S. Clinical efficacy of mirtazapine: a review of meta-analysis of pooled data. Int Clin Psychopharmacol (Suppl) 1995; 10: 25–25
   PubMed Web of Science ®Google Scholar
• Kasper S. Hypericum perforatum – a review of clinical studies. Pharmacopsychiatry 2001; 34(Suppl 1)S51–55
   PubMedGoogle Scholar
• Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed outpatients. A meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology (Berlin) 2002; 164: 301–308
   PubMed Web of Science ®Google Scholar
• Kasper S, Möller HJ. Antidepressive Psychopharmakatherapie: selektive Serotonin-Wiederaufnahmehemmer (SSRI) als neues Wirkprinzip. Deutsches Ärzteblatt 1995; 92: A428–434
   Google Scholar
• Kasper S, Schulz V. [High dose St. John's wort extract as a phytogenic antidepressant]. Wien Med Wochenschr 1999; 149: 191–196
   PubMedGoogle Scholar
• Kasper S, el Giamal N, Hilger E. Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother 2000; 1(4)771–782
   PubMedGoogle Scholar
• Katona C, Bercoff E, Chiu E, Tack P, Versiani M, Woelk H. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. J Affect Disord 1999; 55: 203–213
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16(2)93–100
   PubMed Web of Science ®Google Scholar
• Khisti RT, Chopde CT, Jain SP. Antidepressant-like effect of the neurosteroid 3(-hydroxy-5(-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav 2000; 67: 137–143
   PubMed Web of Science ®Google Scholar
• Kim HL, Streltzer J, Goebert D. St. John's wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 1999; 187: 532–538
   PubMed Web of Science ®Google Scholar
• Kirwin JL, Goren JL. Duloxetine. An antidepressant that inhibits both norepinephrine and serotonin uptake. Formulary 2003; 38: 29–37
   Google Scholar
• Kramer MS. Clinical update: substance P antagonists in patients with major depression. Eur Psychiatry 2002; 17: 10
   Google Scholar
• Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves RJ, Rupniak NMJ. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640–1645
   PubMed Web of Science ®Google Scholar
• Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, Ghosh K, Ball WA, Reines SA, Munjack D, Apter JT, Cunningham L, Kling M, Bari M, Getson A, Lee Y. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004; 29: 385–392
   PubMed Web of Science ®Google Scholar
• Le Quellec A, Dupin S, Tufenkji AE, Genissel P, Houin G. Microdialysis: an alternative for in vitro and in vivo protein binding studies. Pharm Res 1994; 11: 835–838
   PubMedGoogle Scholar
• Lecrubier Y, Bourin M, Moon CAL, et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 1997; 95: 485–493
   PubMed Web of Science ®Google Scholar
• Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 2002; 159: 1361–1366
   PubMed Web of Science ®Google Scholar
• Leinonen, E, Skarstein, J, Behnke, K, Ågren, H, Helsdingen, JT, and the nordic antidepressant study group. 1999. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol, 14:329–337.
   PubMed Web of Science ®Google Scholar
• Lepine JP, Caillard V, Bisserbe JC, Troy S, Hotton JM, Boyer P. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 2004; 161: 836–842
   PubMed Web of Science ®Google Scholar
• Lepola U, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211–217
   PubMed Web of Science ®Google Scholar
• Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram have similar efficacy? a pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004; 19: 149–155
   PubMed Web of Science ®Google Scholar
• Lesieur D, Leclerc V, Chavatte P, Marcot C, Renard P, Guardiola-Lemaitre B. Melatonin: a pertinent prototype for therapeutic intervention. Therapie 1998; 53: 429–437
   PubMedGoogle Scholar
• Linde K, Berner M, Egger M, Mulrow C. St John's wort for depression: meta-analysis of randomised controlled trials. Br J Psychiatry 2005; 186: 99–107
   PubMed Web of Science ®Google Scholar
• Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005; 3: 268–275
   Google Scholar
• Loo H, Dalery J, Macher JP, Payen A. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders]. Encephale 2002a; 28: 356–362
   PubMed Web of Science ®Google Scholar
• Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002b; 17: 239–247
   PubMed Web of Science ®Google Scholar
• Loo H, Dalery J, Macher JP, Payen A. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders]. Encephale 2003; 29: 165–171
   PubMed Web of Science ®Google Scholar
• Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999; 20: 226–247
   PubMed Web of Science ®Google Scholar
• Mace S, Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Exp Opin Pharmacother 2000; 1: 917–933
   PubMedGoogle Scholar
• Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 2006; 62(3)225–233
   PubMed Web of Science ®Google Scholar
• Malhi GS, Mitchell PB. Dual-action antidepressants: Mechanisms of action and clinical use. Prim Psychiatry 2003; 10: 62–66
   Google Scholar
• Malison RT, Anand A, Pelton GH, Kirwin P, Carpenter L, McDougle CJ, Heninger GR, Price LH. Limited efficacy of ketoconazole in treatment-refractory major depression. J Clin Psychopharmacol 1999; 19: 466–470
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Watkin JG, Tran PV. Duloxetine: A new treatment of the emotional and physical symptoms of depression. Primary Care Companion J Clin Psychiatry 2003; 5: 19–28
   PubMedGoogle Scholar
• Mallinckrodt CH, Watkin JG, Liu C, Wohlreich MM, Raskin J. Duloxetine in the treatment of major depressive disorder: A comparison of efficacy in patients with and without melancholic features. BMC Psychiatry 2005; 5: 1
   PubMedGoogle Scholar
• Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999; 14: 73–80
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954–964
   PubMed Web of Science ®Google Scholar
• Möller HJ, Volz HP. Drug treatment of depression in the 1990s. An overview of achievements and future possibilities. Drugs 1996; 52: 625–638
   PubMed Web of Science ®Google Scholar
• Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997; 11: S9–15
   PubMed Web of Science ®Google Scholar
• Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998; 59(Suppl 14)26–29
   PubMed Web of Science ®Google Scholar
• Montgomery, SA. 2005. Benefits and tolerability evaluation of agomelatine: a new approach to the treatment of depressed patients. XIIIth congress of the Association of European Psychiatrists. Implications of the melatonergic system: new perspectives for the treatment of depression; personal communication.
   Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kasper S. Comparison of compliance between serotonergic reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 1995; 9(suppl 4)33–40
   PubMed Web of Science ®Google Scholar
• Montgomery S, Ferguson JM, Schwartz GE. The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol 2003; 23: 45–50
   PubMedGoogle Scholar
• Montgomery, SA, Entsuah, R, Hackett, D, Kunz, NR, Rudolph, RL, Venlafaxine 335 Study Group. 2004a. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry, 65: 328–336.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004b; 50: 57–64
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004c; 19: 271–280
   PubMed Web of Science ®Google Scholar
• Morcuende S, Gadd CA, Peters M, Moss A, Harris EA, Sheasby A, Fisher AS, De Felipe C, Mantyh PW, Rupniak NM, Giese KP, Hunt SP. Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice. Eur J Neurosci 2003; 18: 1828–1836
   PubMed Web of Science ®Google Scholar
• Murphy BEP. Treatment of major depression with steroid suppressive drugs. J Steroid Biochem Mol Biol 1991; 39: 239–244
   PubMed Web of Science ®Google Scholar
• Murphy BEP, Dhar V, Ghadirian AM, Chouinard G, Keller R. Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol 1991; 11: 121–126
   PubMed Web of Science ®Google Scholar
• Murphy BEP, Filipini D, Ghadirian AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 1993; 18: 209–213
   PubMed Web of Science ®Google Scholar
• Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005; 71: 402–408
   PubMed Web of Science ®Google Scholar
• Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM. Biochemical, neurophysiological, and behavioural effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991; 23: 191–199
   Web of Science ®Google Scholar
• Muth ES, Haskins JT, Moyer JA, Husbrands GEM, Nielsen S, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound WY-45,030, an ethyl cyclohexanol derivate. Biochem Pharmacol 1986; 35: 4493–4497
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. 1976. 028 CGI. Clinical global impressions. In: Guy, W, Bonato, RR, editors. Manual for the EDCEU Assessment Battery, 2nd rev. Chevy Chase, MD: National Institute of Mental Health. pp 12-1–12-6.
   Google Scholar
• Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002; 36: 106–132
   PubMedGoogle Scholar
• Nemeroff CB, Owens MJ. Pharmacological differences among the SSRIs: Focus on monoamine transporters and the HPA axis. CNS Spectrums 2004; 6: 23–31
   Google Scholar
• O'Dwyer A-M, Lightman SL, Marks MN, Checkley SA. Treatment of major depression with metyrapone and hydrocortisone. J. Affect, Disord 1995; 33: 123–128
   PubMed Web of Science ®Google Scholar
• Olie JP, Emsley R. Confirmed clinical efficacy of agomelatine (25–50 mg) in major depression: two randomized, double-blind, placebo-controlled studies. Eur Neuropsychopharmacol 2005; 15: S416
   Google Scholar
• Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50: 345–350
   PubMed Web of Science ®Google Scholar
• Papakostas, GI, Fava, M. 2006. A meta-analysis of clinical trials comparing milnacipran, a serotonin-norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol in press (E-pub ahead of print.).
   Google Scholar
• Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Br Med J 1999; 319: 1534–1538
   PubMed Web of Science ®Google Scholar
• Pitsikas N. Duloxetine (Eli Lilly and Co.). Curr Opin Invest Drugs 2000; 1: 116–121
   PubMedGoogle Scholar
• Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32(suppl 1)1–21
   PubMed Web of Science ®Google Scholar
• Preti A. Tomoxetine (Eli Lilly & Co.). Curr Opin Invest Drugs 2002; 3: 272–277
   PubMedGoogle Scholar
• Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs?. J Clin Psychiatry 2001; 62: 358–362
   PubMed Web of Science ®Google Scholar
• Rampello L, Alvano A, Chiechio S, Raffaele R, Vecchio I, Malaguarnera M. An evaluation of efficacy and safety of reboxetine in elderly patients affected by ‘retarded’ post-stroke depression. A random, placebo-controlled study. Arch Gerontol Geriatr 2005; 40: 275–285
   PubMed Web of Science ®Google Scholar
• Rampello L, Chiechio S, Nicoletti G, Alvano A, Vecchio I, Raffaele R, Malaguarnera M. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology (Berlin) 2004; 173: 73–78
   PubMed Web of Science ®Google Scholar
• Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003; 64: 1237–1244
   PubMed Web of Science ®Google Scholar
• Raskin, J, Pritchett, YL, Chappell, AS, D‘Souza, DN, Shen, S, Wernicke, JF. 2005. Duloxetine in the treatment of diabetic peripheral neuropathic pain – results from three clinical trials. Poster, APA, Atlanta, GA.
   Google Scholar
• Raven PW, O'Dwyer A-M, Taylor NF, Checkley SA. The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles. Psychoneuroendocrinology 1996; 21: 277–286
   PubMed Web of Science ®Google Scholar
• Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77–87
   PubMed Web of Science ®Google Scholar
• Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB. Metabolism of some ‘second’- and ‘fourth’-generation antidepressants: Iprindole, viloxazine, bupropion, mainserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 1999; 19: 427–442
   PubMed Web of Science ®Google Scholar
• Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan A. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998; 59: 116–122
   PubMed Web of Science ®Google Scholar
• Rudolph, RL, Feiger, AD, for the Venlafaxine XR 211 Study Group. 1999. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord, 56:171–181.
   PubMed Web of Science ®Google Scholar
• Rupniak NM. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Curr Opin Invest Drugs 2002; 3: 257–261
   PubMedGoogle Scholar
• Rupprecht R. The neuropsychopharmacological potential of neuroactive steroids. J Psychiatr Res 1997; 31: 297–314
   PubMed Web of Science ®Google Scholar
• Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999; 22: 410–416
   PubMed Web of Science ®Google Scholar
• Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2003; 174: 163–176
   Google Scholar
• Sánchez, C, Bøgesø, KP, Ebert, B, Reines, EH. 2004. The role of the R- and S-enanatiomers in the efficacy of citalopram versus escitalopram. 24th Congress of the CINP, Paris.
   Google Scholar
• Schmauss M, Kapfhammer HP, Meyr P, Hoff P. Combined MAO-inhibitor and tri- (tetra) cyclic antidepressant treatment in therapy resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 523–532
   PubMedGoogle Scholar
• Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000; 15: 61–68
   PubMed Web of Science ®Google Scholar
• Schweitzer I, Burrows G, Tuckwell V, Polonowita A, Flynn P, George T, Theodoros M, Mitchell P. Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol 2001; 21: 185–189
   PubMed Web of Science ®Google Scholar
• Settle EC, Stahl SM, Batey SR, Johnston JA, Ascher JA. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 1999; 21: 454–463
   PubMed Web of Science ®Google Scholar
• Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000; 40: 161–167
   PubMed Web of Science ®Google Scholar
• Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U. Effectiveness of St John's wort in major depression: a randomized controlled trial. J Am Med Assoc 2001; 285: 1978–1986
   PubMed Web of Science ®Google Scholar
• Silva RC, Brandao ML. Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: an ethological analysis. Pharmacol Biochem Behav 2000; 65: 209–216
   PubMed Web of Science ®Google Scholar
• Sir A, D'Souza RF, Uguz S, George T, Vahip S, Hopwood M, Martin AJ, Lam W, Burt T. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005; 66: 1312–1320
   PubMed Web of Science ®Google Scholar
• Skinner MH, Skerjanec A, Seger M, Hewitt R. The effect of food and bedtime administration an duloxetine pharmacokinetics [abstract]. Clin Pharmacol Ther 2000; 67: 129
   Web of Science ®Google Scholar
• Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002; 180: 396–404
   PubMed Web of Science ®Google Scholar
• Sovner R, Fogelman S. Ketoconazole therapy for atypical depression. J Clin Psychiatry 2002; 57: 227–228
   Google Scholar
• Stahl S, Zivkov M, Reimitz PE, Panagides J, Hoff W. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies or mirtazapine versus amitriptyline in major depression. Actra Psychiatr Scand 1997; 96(suppl 391)22–30
   Google Scholar
• Stahl SM, Pradko JF, Haight BR. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004; 6: 159–166
   PubMedGoogle Scholar
• Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums 2005; 10: 732–747
   PubMed Web of Science ®Google Scholar
• Steffens DC, Krishnan KRR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis. Depress Anxiety 1997; 6: 10–18
   PubMedGoogle Scholar
• Stout SC, Owens MJ, Nemeroff CB. Neurokinin(1) receptor antagonists as potential antidepressants. Annu Rev Pharmacol Toxicol 2001; 41: 877–906
   PubMed Web of Science ®Google Scholar
• Swindle, RW, Rosenbaum, JF, Mallinckrodt, CH, Lu, Y, Andorn, AC, Watkin, JG, Detke, MJ. 2004. Efficacy of duloxetine treatment: Analysis of pooled data from six placebo- and SSRI-controlled clinical trials. Poster, CINP, Paris, France.
   Google Scholar
• Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. Br Med J 2005; 330: 503
   PubMed Web of Science ®Google Scholar
• Tenn CC, Niles LP. The antidopaminergic action of S-20098 is mediated by benzodiazepine/GABA(A) receptors in the striatum. Brain Res 1997; 756: 293–296
   PubMedGoogle Scholar
• Thakore JH, Dinan TG. Cortisol synthesis inhibition: A new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry 1995; 37: 364–368
   PubMed Web of Science ®Google Scholar
• Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry 1997; 58: 393–398
   PubMed Web of Science ®Google Scholar
• Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149: 195–198
   PubMed Web of Science ®Google Scholar
• Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12: 185–219
   PubMed Web of Science ®Google Scholar
• Thase M, Entsuah A, Rudolph R. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234–241
   PubMed Web of Science ®Google Scholar
• Thase ME, Lu Y, Joliat MJ, Detke MJ. Remission in placebo-controlled trials of duloxetine with an SSRI comparator [abstract]. Biol Psychiatry 2004; 55: 37S
   Google Scholar
• Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, VanMeter S, Harriett AE, Wang Y. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005a; 66: 974–981
   PubMed Web of Science ®Google Scholar
• Thase, ME, Entsuah, R, Ahmed, S, Sloan, DM, Nemeroff, CB. 2005b. Meta-Analysis of randomized controlled trials comparing venlafaxine and SSRIs: The evidence revisited. Prestented at the APA, Atlanta.
   Google Scholar
• Trautmann-Sponsel RD, Dienel A. Safety of Hypericum extract in mildly to moderately depressed outpatients: a review based on data from three randomized, placebo-controlled trials. J Affect Disord 2004; 82: 303–307
   PubMed Web of Science ®Google Scholar
• Trindade E, Menon D, Topfer L-A, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998; 159: 1245–1252
   PubMed Web of Science ®Google Scholar
• Tuma S, Strubbe JJ, Mocaer E, Koolhaas JM. S20098 affects the free-running rhythms of body temperature and activity and decreases light-induced phase delay of circadian rhythms of the rat. Chronobiol Int 2002; 18: 781–799
   Web of Science ®Google Scholar
• Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 2001; 24: 511–521
   PubMed Web of Science ®Google Scholar
• Tylee A, Beaumont G, Bowden MW, et al. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry 1997; 3: 51–58
   Google Scholar
• Uebelhack R, Gruenwald J, Graubaum HJ, Busch R. Efficacy and tolerability of Hypericum extract STW 3–VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Adv Ther 2004; 21: 265–275
   PubMedGoogle Scholar
• Van Reeth O, Olivares E, Zhang Y, Tripathi B, Turek FW. Chronobiotic effects of gepirone, a potential antidepressant with 5HT1A receptor partial agonist properties. Behav Pharmacol 1999; 10: 119–130
   PubMedGoogle Scholar
• Versiani M, Mehilane L, Gaszner P, rnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 1999; 60: 400–406
   PubMed Web of Science ®Google Scholar
• Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000; 20: 28–34
   PubMed Web of Science ®Google Scholar
• Vis PM, van BM, Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005; 39: 1798–1807
   PubMed Web of Science ®Google Scholar
• Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders – a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 1997; 30: 1–5
   PubMed Web of Science ®Google Scholar
• Volz HP, Laux P. Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine. Comp Psychiatry 2000; 41: 133–137
   PubMedGoogle Scholar
• Wang CP, Howell SR, Scatina J, Sisenwine SF. The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine. Chirality 1992; 4: 84–90
   PubMed Web of Science ®Google Scholar
• Weihs KL, Houser TL, Batey SR, Ascher JA, Bolden-Watson C, Donahue RMJ, Metz A. Continuation phase treatment with bupropion SR effectively decreases the risk of relapse of depression. Biol Psychiatry 2002; 51: 753–761
   PubMed Web of Science ®Google Scholar
• Wheatley, DP, van Moffaert, M, Timmerman, L, Kremer, CME, and the mirtazapine-fluoxetine study group. 1998. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry, 59:306–312.
   PubMedGoogle Scholar
• Wilcox CS, Ferguson JM, Dale JL, Heiser JF. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull 1996; 32: 335–342
   PubMed Web of Science ®Google Scholar
• Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. Br Med J 2000; 321: 536–539
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI, Manfredi F, Ingbar J, Brizendine L, Weingartner H. Ketoconazole administration in hypercortisolemic depression. Am J Psychiatry 1993; 150: 810–812
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, Ormiston S, Johnson R, Canick J, Brizendine L, Weingartner H. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997; 41: 311–318
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson R, Canick J. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry 1999a; 45: 1070–1074
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999b; 156: 646–649
   PubMed Web of Science ®Google Scholar
• Wong AH, Smith M, Boon HS. Herbal remedies in psychiatric practice. Arch Gen Psychiatry 1998; 55: 1033–1044
   PubMed Web of Science ®Google Scholar
• Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignori A, Carfagna N, McArthur RA. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 2000; 47: 818–829
   PubMed Web of Science ®Google Scholar
• Yatin SM, Miller GM, Norton C, Madras BK. Dopamine transporter-dependent induction of C-fos in HEK cells. Synapse 2002; 45: 52–65
   PubMedGoogle Scholar
• Zlotos DP. Recent advances in melatonin receptor ligands. Arch Pharm (Weinheim) 2005; 338: 229–247
   PubMed Web of Science ®Google Scholar
• Zobel AW, Nickel T, Künzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000; 34: 171–181
   PubMed Web of Science ®Google Scholar